CD274 and neoplasm: Similarly, Briere et al. reported that in a syngeneic tumor model, a class I/IV HDACi (mocetinostat) increased PD-L1 expression and exhibited a significantly improved antitumor immune response in combination with anti-PD-L1 therapy157.